Abstract | PURPOSE: PATIENTS AND METHODS: Patients with a histologic diagnosis of limited-stage unresectable thymoma or thymic carcinoma were eligible. Further requirements included a Karnofsky Performance Score of > 60, no prior radiation to the chest, and adequate bone marrow, hepatic, and renal function. No patient had undergone chemotherapy previously. Patients received two to four cycles (repeated every 3 weeks) of cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) followed by a total dosage of 54 Gy to the primary tumor and regional lymph nodes for patients with a stable, partial, or complete response to chemotherapy. RESULTS: From November 1983 through January 1995, 26 patients were entered onto the trial. Three patients were ineligible on the basis of pathologic review ( lung cancer, germ cell cancer, lymphoma). Toxicity, primarily hematologic, was mild, with only one early death due to a perforated abdominal viscus. Among the 23 assessable patients, there were five complete and 11 partial responses to chemotherapy (overall response rate, 69.6%). The median time to treatment failure was 93.2 months (range, 3 to 99.2+ months), and the median survival time was 93 months (range, 1 to 110 months). The 5-year survival rate is 52.5%. CONCLUSIONS:
|
Authors | P J Loehrer Sr, M Chen, K Kim, S C Aisner, L H Einhorn, R Livingston, D Johnson |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 15
Issue 9
Pg. 3093-9
(Sep 1997)
ISSN: 0732-183X [Print] United States |
PMID | 9294472
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Doxorubicin
- Cyclophosphamide
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Radiotherapy, Adjuvant
- Survival Analysis
- Thymoma
(drug therapy, pathology, radiotherapy)
- Thymus Neoplasms
(drug therapy, pathology, radiotherapy)
- Treatment Failure
- Treatment Outcome
|